by

A multicenter, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CNTY-101 in patients with relapsed or refractory CD19-positive B-cell lymphomas.

Now Recruiting

Learn more about Century’s current Phase 1 clinical trial, ELiPSE-1, with study ID number: NCT05336409 at clinicaltrials.gov.

Patient Flyer
Download
Descargar

by

A multicenter, dose-finding study to evaluate the safety and efficacy of CNTY-101 in patients with B cell-mediated autoimmune diseases (systemic lupus erythematosus and lupus nephritis).

Now Recruiting

Learn more about Century’s current Phase 1 clinical trial, CALiPSO-1, with study ID number: NCT06255028 at clinicaltrials.gov.

Patient Flyer
Download
Descargar